Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Performance evaluation of QIAstat-Dx® GI2 Panel using the QIAstat-Dx® Analyzer to demonstrate that the QIAstat-Dx® GI2 Panel achieves its intended performance during normal conditions of use by the intended user in the intended environment
The objective of the study is to demonstrate that the QIAstat-Dx® Gastrointestinal Panel 2 achieves its intended performance during normal conditions of use by the intended user in the intended environment.
The primary objective is to evaluate the performance of QIAstat-Dx® GI2 Panel in comparison with the results obtained from the reference methods.
The secondary objective of the study is to evaluate the safety of QIAstat-Dx® GI2 Panel with respect to users/operators.
The primary study endpoint will be the results for each analyte obtained from testing prospective and retrospective specimens with QIAstat-Dx® GI2 Panel and Reference Method(s). Positive Percent Agreement (PPA) and Negative Percent Agreement (NPA) will be determined
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Clinical sensitivity | Positive percent agreement PPA | 8 months |
| Clinical specificity | Negative percent agreement NPA | 8 months |
Not provided
Not provided
Inclusion Criteria:
Stool specimen must have been collected from subjects/patients which meet the institute's criteria for a suspected enteric pathogen, such as individuals presenting with symptoms of gastrointestinal infection;
Stool specimen will be residual and obtained for completion of routine gastrointestinal testing;
Specimen for testing will consist of stool specimens preserved in Cary- Blair medium following the manufacturer's instructions for use;
Fresh, unpreserved stool must be transferred to Cary-Blair as soon as possible after specimen collection;
When fresh stool is transferred into the Cary-Blair container, the maximum fill line of the container should not be exceeded;
There is an adequate residual volume (minimum 1.0 mL) of Cary- Blair preserved stool specimens;
Cary- Blair preserved stool specimens should represent a homogenous suspension (easily vortexed);
Cary- Blair preserved stool specimens have been stored at the following conditions prior testing:
Samples should be tested on the QIAstat-Dx® system and the reference method FilmArray within 3 hours of each other.
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Patients with signs and symptoms of gastrointestinal infection
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Sarah Johnson | Qiagen Manchester Limited | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| QIAGEN | Manchester | United Kingdom |
Not provided
Not provided
Not provided
Not provided
Fresh stool specimens in Cary-Blair transport media. Selected archived frozen stool specimens in Cary-Blair transport media will be tested retrospectively if required.